CRMD at a glance
CorMedix Inc. (CRMD, SEC CIK 1410098) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on August 13, 2026, an 8-K current report on August 13, 2026 and Form 4 insider filings as recently as September 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), CorMedix Inc. (CRMD) reported revenue of $311.7 million (up 617.0% from FY2024) and net income of $163.1 million. Diluted EPS was $2.04.
- As of June 30, 2026, 28 institutional investment managers tracked by SignalX reported holding CorMedix Inc. (CRMD) shares worth $128.8 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $311.7M
- +617.0% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 28 funds
- $128.8M · +2 vs prior quarter
- Latest 8-K
- Aug 13, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue and grant income $101.9M, up 157% YoY from $39.7M
- Gross margin 75.6% vs 95.3% YoY; operating margin 42.1% vs 49.2%
- Best performer DefenCath sales $66.1M vs $39.7M; Melinta Portfolio $28.2M
- Cash, equivalents and short-term investments $256.7M vs $148.5M at December 31, 2025
- Operating cash flow $128.6M vs $49.7M; financing used $19.2M
- DefenCath post-TDAPA transition expected to reduce second-half 2026 net sales; 2027 payment could increase meaningfully
Risk Factors
- Risk-factor section not provided; no quarter-specific risk changes identifiable
- Share repurchase authorization: up to $75 million through December 31, 2027
- Repurchase liquidity use: $6.4 million remaining after 814,281 shares purchased at $7.85
AI summary of the CRMD 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1, containing the detailed financial results
Item 8.01: Other Events
- Preliminary approval granted for settlement of consolidated derivative litigation against CorMedix-related parties
- Final settlement hearing scheduled for September 23, 2026, before the U.S. District Court for New Jersey
Item EX-99.1: Item EX-99.1
- Proposed settlement resolves derivative litigation alleging fiduciary breaches tied to DefenCath manufacturing deficiencies and delayed FDA approval
- CorMedix to implement or maintain corporate-governance reforms for at least 3.5 years
Item 8.01: Other Events
- Elizabeth Hurlburt promoted to Chief Operating and Commercial Officer on June 29, 2026
- Expanded remit covers commercial functions, medical affairs, regulatory and clinical operations
AI summaries of CRMD 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CRMD
Don't miss the next CRMD filing
- Alerts as it files. A push when CRMD files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CRMD, by share count.
- Ask anything. An AI agent that reads every CRMD filing and answers with sources.
CRMD alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Dillione Janet | M | Sep 18, 2026 | 48,909 | - |
| Dillione Janet | M | Sep 18, 2026 | 48,909 | - |
| Zelnick Kaufman Beth | F | Aug 29, 2026 | 8,424 | $8.30 |
| Blum Susan | F | Aug 29, 2026 | 8,424 | $8.30 |
| Hurlburt Elizabeth | F | Aug 29, 2026 | 8,076 | $8.30 |
| Todisco Joseph | A | Feb 4, 2026 | 77,156 | - |
| Hurlburt Elizabeth | A | Feb 4, 2026 | 36,006 | - |
| Zelnick Kaufman Beth | A | Feb 4, 2026 | 36,006 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $43.5M | $311.7M |
| Gross Profit | - | $40.3M | $275.7M |
| Operating Income | - | -$22.4M | $150.1M |
| Net Income | - | -$17.9M | $163.1M |
| Gross Margin | - | 92.7% | 88.5% |
| Op. Margin | - | -51.4% | 48.2% |
| Net Margin | - | -41.2% | 52.3% |
| Balance Sheet | |||
| Total Assets | $82.1M | $118.8M | $826.1M |
| Equity | - | $84.7M | $405.3M |
| ROE | - | -21.2% | 40.2% |
| Per Share | |||
| EPS | - | $-0.30 | $2.04 |
| Cash Flow | |||
| Operating CF | - | -$50.6M | $175.0M |
| CapEx | $327K | $116K | $2.3M |
Source: XBRL data in CorMedix Inc. (CRMD)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate CRMD share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 28 | $128.8M |
| Q1 2026 | 26 | $107.2M |
| Q4 2025 | 25 | $201.8M |
| Q3 2025 | 24 | $213.0M |
| Q2 2025 | 26 | $207.5M |
| Q1 2025 | 21 | $53.5M |
| Q4 2024 | 18 | $57.4M |
| Q3 2024 | 11 | $21.3M |
- BlackRock+356.5K (+6%)
- State Street Corp+125.0K (+6%)
- Northern Trust+118.7K (+19%)
- Raymond James Financial+117.9K (+36%)
- Wells Fargo & Co+36.5K (+112%)
- Citadel Advisors LLC−186.0K (-77%)
- AQR Capital Management−83.2K (-35%)
- JPMorgan Chase & Co−48.5K (-42%)
- Goldman Sachs Group−44.9K (-9%)
- Vanguard Portfolio Management LLC−34.0K (-5%)
- D.E. Shaw & Co+171.8K
- Allstate+16.7K
Source: 13F-HR filings on SEC EDGAR (aggregated from 179 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CRMD filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 18, 2026 | - | - | - |
| 4 | Sep 1, 2026 | - | - | - |
| 4 | Sep 1, 2026 | - | - | - |
| 4 | Sep 1, 2026 | - | - | - |
| 10-Q | Aug 13, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 13, 2026 | - | Analysis | - |
| 8-K | Aug 7, 2026 | - | Analysis | - |
| 8-K | Jul 2, 2026 | - | Analysis | - |
| 8-K | Jul 1, 2026 | - | Analysis | - |
| 8-K | Jun 24, 2026 | - | Analysis | - |
| 8-K | Jun 8, 2026 | - | Analysis | |
| 8-K | May 14, 2026 | - | Analysis | |
| 10-Q | May 14, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Apr 27, 2026 | - | Analysis | - |
| 8-K | Mar 6, 2026 | - | Analysis | - |
| 10-K | Mar 5, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 5, 2026 | - | Analysis | - |
| 4 | Feb 6, 2026 | - | - | |
| 4 | Feb 6, 2026 | - | - | |
| 4 | Feb 6, 2026 | - | - | |
| 4 | Jan 27, 2026 | - | - | |
| 4 | Jan 27, 2026 | - | - | |
| 4 | Jan 27, 2026 | - | - | |
| 4 | Jan 27, 2026 | - | - | |
| 4 | Jan 27, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
CRMD SEC filings: frequently asked questions
Which institutions hold CRMD stock?
As of June 30, 2026, the largest CorMedix Inc. (CRMD) holders among the 13F filers tracked by SignalX were BlackRock ($49.6 million), Vanguard Capital Management LLC ($24.6 million), State Street Corp ($18.2 million), Northern Trust ($5.9 million), Vanguard Portfolio Management LLC ($5.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was CRMD's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), CorMedix Inc. (CRMD) reported revenue of $311.7 million (up 617.0% from FY2024) and net income of $163.1 million. Diluted EPS was $2.04. The figures come from the XBRL data in the 10-K.
What did CRMD report in its latest 8-K?
CorMedix Inc. (CRMD) filed an 8-K on August 13, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 2026 financial results for quarter ended June 30, 2026.
What are the latest CRMD SEC filings?
CorMedix Inc. (CRMD) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on August 13, 2026, an 8-K current report on August 13, 2026 and a Form 4 insider filing on September 18, 2026.
What is CRMD's SEC CIK number?
CorMedix Inc. (CRMD)'s SEC Central Index Key (CIK) is 1410098. EDGAR lists every CRMD filing under that number.
Ask anything about CRMD
The research agent reads CRMD's filings, financials, insider trades and 13F holders, then answers with sources.